Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Commercialization Grant Awards Announced By Life Sciences Discovery Fund
The Life Sciences Discovery Fund (LSDF) has announced $300,000 in awards from its inaugural winter commercialization grant competition to support commercial translation of health-related technologies by two Washington state-based research teams. Commercialization grants are designed to facilitate the transition of promising ideas or technologies from Washington"s non-profit research sector into marketable products and services that can improve health, foster economic growth, and promote life sciences competitiveness in the state. The grants support proof-of-concept experiments and prototype development activities that are expected to lower the risk of commercialization and help new technologies cross the "valley of death" - that stage of the commercialization pathway where development funding is particularly scarce.

2009/044 NICE Guidance Recommends Tenofovir Disoproxil For Hepatitis B
The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published final guidance recommending the use of tenofovir disoproxil for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.
News of the day
Long-Suffering Rohingya In Bangladesh Face Unacceptable Abuse
Thousands of unregistered Rohingya refugees living in the Kutupalong makeshift camp, Bangladesh, are being forcibly displaced from their homes, in an act of intimidation and abuse by the local authorities. The international medical organization Doctors Without Border/Mç©decins Sans Frontiç¨res (MSF) has treated numerous people for injuries, of which the majority were women and children. Furthermore, MSF has witnessed countless destroyed homes and heard many reports of people being warned to remove their own shelters or face the consequences.
Nutrition

CRi Oosight(TM) Instrument Crucial In IVF Breakthrough Demonstrating A Correlation Between Non-Invasive Egg Metrics And Pregnancy

Cambridge Research & Instrumentation, Inc. (CRi) announced that Oosight(TM), a non-invasive optical imaging system manufactured by CRi and widely used by embryologists as an aid in the field of in vitro fertilization (IVF), has been used in a groundbreaking study that investigated ways to select eggs most likely to produce a pregnancy. Dr. Suha Kilani, senior scientist at IVF Australia in Sydney, led a group which included researchers from the School of Women"s & Children"s Health at the University of New South Wales. The group determined that while absolute predictive criteria for the selection of the best embryo for single-embryo transfer remain elusive, CRi"s Oosight instrument provides a useful, non-invasive means to accurately measure characteristics of the egg to help identify the most viable embryo even before fertilization occurs. The results are the first to show a direct link between egg spindle characteristics and pregnancy. "Extrapolation of these results would suggest that when a normal spindle is found, the chances of a pregnancy, if a high quality cleavage stage embryo follows, is greater than 65%," commented Dr. Kilani. "We congratulate Dr. Kilani and her collaborators on the quality of their work. It is a significant step forward in improving methods of non-invasive grading criteria. This study adds to our knowledge of contributing factors to fertility and also validates the importance of good quantitative data as produced with the Oosight system. Such data are imperative if we are to make single-embryo transfer a reality, thereby greatly reducing the risks associated with multiple births," said Cathy Boutin, Product Manager at CRi. CRi"s Oosight systems based upon the company"s original LC-PolScope technology can be seen at the European Society for Human Reproduction and Embryology conference in Amsterdam June 28 to July 2 in the Research Instrument"s booth (number 95). Oosight systems produce non-invasive, high-contrast images of the meiotic spindle and zona pellucida without the need for potentially harmful dyes or stains. In addition, these images contain quantitative data that indicate the relative order of structures within the spindle and zona. In this study, spindle density was significantly higher in those oocytes resulting in pregnancy. The work by Dr. Kilani"s group, "Are there non-invasive markers in human oocytes that can predict pregnancy outcome?" was published in March by Reproductive BioMedicine Online. Cambridge Research & Instrumentation, Inc (CRi) is a biomedical imaging company providing innovative optical imaging solutions for over 20 years. CRi"s multidisciplinary team is dedicated to providing comprehensive solutions and support enabling our customers to produce breakthroughs in research and medical care. With a focus on addressing customer needs coupled to a commitment to advancing the field of personalized medicine, CRi helps scientists and clinicians extract new disease-specific information from biological samples in the physiological, morphological, and biochemical context of intact tissues and organisms. CRi"s award-winning innovations are being recognized for their novel and groundbreaking capabilities in academic research to pharmaceutical drug development to clinical medicine, including a 2009 Top 10 Medical Innovations of the Year award from Cleveland Clinic and a 2009 Frost and Sullivan Product Line Strategy award. Cambridge Research and Instrumentation, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009